In this work, a graphene oxide-based nanoformulation was designed to deliver a high concentration of doxorubicin to osteosarcoma cancer cells. This nanoformulation showed a better release profile in an acidic condition of tumor site, and higher cytotoxicity and apoptosis rate in comparison to free doxorubicin, which suggests, it is a potential platform for targeted therapy of osteosarcoma.